样式: 排序: IF: - GO 导出 标记为已读
-
Acceptance Testing of Used Cascade Impactor Stages Based on Pressure Drop Measurements in a Flow System Managed with a Critical Flow Venturi: Part II-Quantification of the Test Uncertainty Ratio for Pass/Fail Decision-Making under Pharmacopeial Constraints. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-11-29 Daryl L Roberts
Background: The pressure drop at any cascade impactor stage is related to the open area of nozzles at that stage. Pressure drop measurement therefore can potentially test whether the nozzles of a given stage are within the range specified for continued use for testing of inhalable drug products. Previous such efforts, however, have been hindered by the measurement precision required for making a pass/fail
-
Acceptance Testing of Used Cascade Impactor Stages Based on Pressure Drop Measurements in a Flow System Managed with a Critical Flow Venturi: Part I-Laboratory Proof-of-Principle. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-11-29 Daryl L Roberts
Background: Cascade impactors are essential for measuring the aerodynamic particle size distribution delivered by metered dose, dry powder, and similar inhalable drug products. For quality control of used impactors, periodic optical inspection of the nozzles of each impactor stage (stage mensuration) is currently the only method sufficiently precise to test whether used impactors are suitable for continued
-
Dry Powder Inhalers: From Bench to Bedside. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-11-28 Henry Chrystyn,Wahida Azouz,Walid Tarsin
Dry powder inhalers (DPIs) are now widely prescribed and preferred by the majority of patients. These devices have many advantages over the traditional pressurized metered-dose inhaler (pMDI) but they do have disadvantages. The characteristics of the dose emitted from a DPI are affected by the inhalation manoeuvre used by a patient. Each patient is different and the severity of their lung disease varies
-
Effectiveness of Nebulized Tranexamic Acid in Patients with Moderate-to-Massive Hemoptysis at a Tertiary Academic Medical Center. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-11-14 Afrah Alkazemi,Mary Kovacevic,Kevin Dube,Julie C Lauffenburger,Adam Smith,Stephen Malinowski,Gerald L Weinhouse
Introduction: The management of severe hemoptysis mainly consists of invasive interventional procedures, including angiographic bronchial artery embolization, various endobronchial interventions, and sometimes surgery. However, there are limited effective noninvasive medical therapies available. The objective of this analysis was to evaluate the effectiveness and safety of nebulized tranexamic acid
-
Abstracts from The International Society for Aerosols in Medicine. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-10-30
-
Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-10-16 Kohei Togami,Yukimune Kanehira,Yuki Yumita,Hiroaki Ozaki,Rui Wang,Hitoshi Tada,Sumio Chono
Background: A distinctive pathological feature of idiopathic pulmonary fibrosis (IPF) is the aberrant accumulation of extracellular matrix components in the alveoli in abnormal remodeling and reconstruction following scarring of the alveolar structure. The current antifibrotic agents used for IPF therapy frequently result in systemic side effects because these agents are distributed, through the blood
-
A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-09-22 Hiroyuki Doi,Jun Atsumi,David Baratz,Yohei Miyamoto
Purpose: TRK-250 is a novel single-stranded oligonucleotide carrying a human Transforming growth factor-beta 1-targeting siRNA motif tethered by two proline linkers. Nonclinical studies have shown that TRK-250 may have potency to prevent the progression of pulmonary fibrosis. Herein, a phase I study was conducted to investigate the safety and pharmacokinetics (PKs) of TRK-250 in patients with idiopathic
-
Aerosol Delivery of a Novel Recombinant Modified Superoxide Dismutase Protein Reduces Oxidant Injury and Attenuates Escherichia coli Induced Lung Injury in Rats. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-08-28 Sean D McCarthy,Maura A Tilbury,Claire H Masterson,Ronan MacLoughlin,Héctor E González,John G Laffey,J Gerard Wall,Daniel O'Toole
Background: Acute respiratory distress syndrome (ARDS) is a life-threatening respiratory failure syndrome with diverse etiologies characterized by increased permeability of alveolar-capillary membranes, pulmonary edema, and acute onset hypoxemia. During the ARDS acute phase, neutrophil infiltration into the alveolar space results in uncontrolled release of reactive oxygen species (ROS) and proteases
-
There Is a Risk of Spread During a Nebulization Session in a Patient with COVID-19. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-08-22 Christophe Thibon,Laurent Vecellio,Leila Belkhir,Jean-Christophe Dubus,Annie Robert,Benoît Kabamba,Gregory Reychler
Introduction: A hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential environmental contamination by the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session. Methods: In this cohort study, COVID-19
-
Measuring Anatomical Distributions of Ventilation and Aerosol Deposition with PET-CT. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-08-01 Jose G Venegas
In disease, lung function and structure are heterogeneous, and aerosol transport and local deposition vary significantly among parts of the lung. Understanding such heterogeneity is relevant to aerosol medicine and for quantifying mucociliary clearance from different parts of the lung. In this chapter, we describe positron emission tomography (PET) imaging methods to quantitatively assess the deposition
-
Magnetic Resonance Imaging of Aerosol Deposition. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-07-31 Richard B Thompson,Chantal Darquenne
Nuclear magnetic resonance imaging (MRI) uses non-ionizing radiation and offers a host of contrast mechanisms with the potential to quantify aerosol deposition. This chapter introduces the physics of MRI, its use in lung imaging, and more specifically, the methods that are used for the detection of regional distributions of inhaled particles. The most common implementation of MRI is based on imaging
-
The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-07-11 Bahar Arslan,Gülden Paçacı Çetin,İnsu Yilmaz
The journey of using anticholinergics in the treatment of asthma started with anticholinergic-containing plants such as Datura stramonium and Atropa belladonna, followed by ipratropium bromide and continued with tiotropium, glycopyrronium, and umeclidinium. Although antimuscarinics were used in the maintenance treatment of asthma over a century ago, after a long time (since 2014), it has been recommended
-
Bioequivalence of Two Tiotropium Dry Powder Inhalers and the Utility of Realistic Impactor Testing. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-06-26 Clarissa Gobetti,Sanjeeva Dissanayake,Jag Shur,William Ganley,Lucas Silva,Isam Salem,Omaima Najib,Usama Harb
Introduction: Inhaled antimuscarinics are a cornerstone of the management of chronic obstructive pulmonary disease. This article details a series of five pharmacokinetic (PK) studies comparing a generic tiotropium dry powder inhaler (DPI) to Spiriva HandiHaler, the realistic in vitro methods used to support those studies, and the related in vitro-in vivo correlations (IVIVCs). Methods: All five PK
-
Aerosol Particle Size Influences the Infectious Dose and Disease Severity in a Golden Syrian Hamster Model of Inhalational COVID-19. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-06-01 Jeremy A Boydston,Jennifer Biryukov,John J Yeager,Heather A Zimmerman,Gregory Williams,Brian Green,Amy L Reese,Katie Beck,Jordan K Bohannon,David Miller,Denise Freeburger,Amanda Graham,Victoria Wahl,Michael C Hevey,Paul A Dabisch
Background: Significant evidence suggests that SARS-CoV-2 can be transmitted via respiratory aerosols, which are known to vary as a function of respiratory activity. Most animal models examine disease presentation following inhalation of small-particle aerosols similar to those generated during quiet breathing or speaking. However, despite evidence that particle size can influence dose-infectivity
-
Multidrug Aerosol Delivery During Mechanical Ventilation. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-30 Ann D Cuccia,Michael McPeck,Janice A Lee,Gerald C Smaldone
Background: In the critically ill, pulmonary vasodilators are often provided off label to intubated patients using continuous nebulization. If additional aerosol therapies such as bronchodilators or antibiotics are needed, vasodilator therapy may be interrupted. This study assesses aerosol systems designed for simultaneous delivery of two aerosols using continuous nebulization and bolus injection without
-
Abstracts from The Aerosol Society Drug Delivery to the Lungs 33. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-24
-
Dynamic Analysis of Aerosol Release from a Pressurized Metered Dose Inhaler Combined with a Valved Holding Chamber Using Simplified Laser Photometry. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-22 Tetsuri Kondo,Toshimori Tanigaki,Makoto Hibino,Sakurako Tajiri,Shigeto Horiuchi,Kazunari Maeda,Shunichi Tobe,Riko Kamada
Background: A pressurized metered dose inhaler combined with a valved holding chamber (pMDI+VHC) is used to prevent upper airway complications and improve the efficiency of inhaled drug delivery; however, the aerodynamic behavior of the released particles has not been well investigated. This study aimed at clarifying the particle release profiles of a VHC using simplified laser photometry. Methods:
-
Predicting Inhaled Drug Dose Generated by Mesh Nebulizers. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-19 Yu-Chung Hsu,Hsin-Hsien Li,Li-Chung Chiu,Wen-Chieh Chiang,Tien-Pei Fang,Hui-Ling Lin
Background: The lung dose of nebulized drugs for spontaneous breathing is influenced by breathing patterns and nebulizer performance. This study aimed to develop a system for measuring breath patterns and a formula for estimating inhaled drugs, and then to validate the hypothesized prediction formula. Methods: An in vitro model was first used to determine correlations among the delivered dose, breath
-
In Vitro Effect of Combined Hypertonic Saline and Salbutamol on Ciliary Beating Frequency and Mucociliary Transport in Human Nasal Epithelial Cells of Healthy Volunteers and Patients with Cystic Fibrosis. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-17 Anaïs Escher,Elisabeth Kieninger,Susan De Groof,Sibel T Savas,Martin Schneiter,Stefan A Tschanz,Martin Frenz,Philipp Latzin,Carmen Casaulta,Loretta Müller
Background: Inhalation of hypertonic saline (HS) is standard of care in patients with cystic fibrosis (CF). However, it is unclear if adding salbutamol has-besides bronchodilation-further benefits, for example, on the mucociliary clearance. We assessed this in vitro by measuring the ciliary beating frequency (CBF) and the mucociliary transport rate (MCT) in nasal epithelial cells (NECs) of healthy
-
Nanoparticle Diffusion in Respiratory Mucus Influenced by Mucociliary Clearance: A Review of Mathematical Modeling. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-15 Mohammad Hadi Sedaghat,Mehrdad Behnia,Omid Abouali
Background: Inhalation and deposition of particles in human airways have attracted considerable attention due to importance of particulate pollutants, transmission of infectious diseases, and therapeutic delivery of drugs at targeted areas. We summarize current state-of-the art research in particle deposition on airway surface liquid (ASL) influenced by mucociliary clearance (MCC) by identifying areas
-
Minimizing Aerosol Leakage from Facemasks in the COVID-19 Pandemic. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-12 Mylene G H Frankfort,Iris Lauwers,Emerentia M C Pruijn,Sjoerd F Dijkstra,Liza H G Boormans,Nicolaas A Schouten,Corrinus C van Donkelaar,Hettie M Janssens,
Background: Aerosol therapies with vented facemasks are considered a risk for nosocomial transmission of viruses such as severe acute respiratory syndrome coronavirus 2. The transmission risk can be decreased by minimizing aerosol leakage and filtering the exhaled air. Objective: In this study, we determined which closed facemask designs show the least leakage. Methods: Smoke leakage was quantified
-
Flow Resistance of the Micro-Orifice Collector in the Next Generation Impactor. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-05-04 Daryl L Roberts
-
Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Subsets: Rationale and Clinical Applications. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-04-20 Simone Redaelli,Matteo Pozzi,Marco Giani,Aurora Magliocca,Roberto Fumagalli,Giuseppe Foti,Lorenzo Berra,Emanuele Rezoagli
Acute respiratory distress syndrome (ARDS) is a life-threatening condition, characterized by diffuse inflammatory lung injury. Since the coronavirus disease 2019 (COVID-19) pandemic spread worldwide, the most common cause of ARDS has been the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Both the COVID-19-associated ARDS and the ARDS related to other causes-also defined as
-
Effect of Age and Head Position on Total and Regional Aerosol Deposition in Three-Dimensional Models of Human Intranasal Airways Using a Mucosal Atomization Device. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-04-14 Jana S Kesavan,Kristina Kuypers,Douglas R Sommerville,Keith Sedberry,Beth L Laube
Background: This study examined the effect of age and head position on total and regional deposition of aerosol delivered by a mucosal atomization device (MAD™) in three-dimensional (3D) models of the intranasal airways of an 18-, 5-, and 2-year-old human. Models consisted of four pieces: anterior nose and nasal cavity that was divided horizontally into upper, middle, and lower thirds. Methods: Models
-
Pressure Drop Characteristics of the Reduced NGI Configuration with Several Common Glass Fiber Filters. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-03-10 Daryl L Roberts
Background: Measurement of aerodynamic particle size distribution, a clinically relevant in vitro attribute of inhalable drug products, involves multistage cascade impactors and is tedious and expensive. A leading candidate for a quicker method is the reduced NGI™ (rNGI). This method involves placing glass fiber filters on top of the nozzles of a chosen NGI stage, selected often to collect all particles
-
Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-02-23 Edgar Hernan Cuevas Brun,Zuo-Yi Hong,Yuan-Ming Hsu,Ciou-Ting Wang,Dai-Jung Chung,Shang-Kok Ng,Yau-Hsuan Lee,Tzu-Tang Wei
Background: Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by lung scarring, which results in breathing difficulty. Currently, patients with IPF exhibit a poor survival rate and have access to very limited therapeutic options. Interferon beta (IFN-β) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis
-
Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy Volunteers. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-02-16 Sanjeeva Dissanayake,Gill Mundin,Jo Woodward,Mark Lomax,Prashant Dalvi
Introduction: Fluticasone propionate/formoterol fumarate (fluticasone/formoterol) exposures, following administration of Flutiform® K-haler®, a breath-actuated inhaler (BAI), were compared with the Flutiform pressurized metered-dose inhaler (pMDI) with/without spacer in two healthy volunteer studies. In addition, formoterol-induced systemic pharmacodynamic (PD) effects were examined in the second study
-
In Vitro Drug Delivery of a Fixed-Dose Combination of Fluticasone Furoate/Umeclidinium/Vilanterol from a Dry Powder Inhaler J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-01-25 Melanie Hamilton, Martin Anderson, Rajiv Dhand, Oonagh Patmore, David Prime, Edward Taylor
Background: Dry powder inhalers (DPIs) require patients to impart sufficient energy through inhalation to ensure adequate dose emission, medication deaggregation, and resultant particle sizes suitable for lung deposition. There is an ongoing debate regarding the level of inspiratory effort, and therefore inspiratory flow rate, needed for optimal dose delivery from DPIs.
-
Resveratrol-Loaded Dipalmitoylphosphatidylcholine Liposomal Large Porous Microparticle Inhalations for the Treatment of Bacterial Pneumonia Caused by Acinetobacter baumannii J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-01-24 Zicheng Yu, Tingting Wu, Xiaoyan Liu, Hongjun Chen, Chunxia Ren, Lifei Zhu
Background:Acinetobacter baumannii-mediated bacterial pneumonia is a common disease that is harmful to human health. Dipalmitoylphosphatidylcholine (DPPC) is the major lipid component of the pulmonary surfactant (PS) found in the alveolar space; the PS helps to keep surface tension low, which allows for improved oxygen delivery. Resveratrol (RE) is a phytoalexin found in plants that is released in
-
Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2023-01-13 Feras Hawari, Yasmeen Dodin, Rabab Tayyem, Samer Najjar, Hanan Kakish, Mohammed Abu Fara, Abdullah Al Zou'bi, Nasir Idkaidek
Background: Early in the coronavirus disease 2019 (COVID-19) pandemic, hydroxychloroquine (HCQ) drew substantial attention as a potential COVID-19 treatment based on its antiviral and immunomodulatory effects in vitro. However, HCQ showed a lack of efficacy in vivo, and different groups of researchers attributed this failure to the insufficient drug concentration in the lung following oral administration
-
Positron Emission Tomography-Computed Tomography Imaging of Selective Lobar Delivery of Stem Cells in Ex Vivo Lung Model of Mechanical Ventilation J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-30 Luiz Maracaja, Ashish K. Khanna, Sean V. Murphy, Danielle L.V. Maracaja, Magan R. Lane, Oula Khoury, Josh Tan, Naresh Damuka, Freda F. Crawford, Joseph A. Bottoms, Mack D. Miller, David W. Kaczka, James Eric Jordam, Kiran Kumar Solingapuram Sai
Introduction: The delivery of cell therapies may be an important frontier to treat different respiratory diseases in the near future. However, the cell size, delivery conditions, cell viability, and effect in the pulmonary function are critical factors. We performed a proof-of-concept experiment using ex vivo lungs and novel subglottic airway device that allows for selective lobar isolation and administration
-
The Use of Single Photon Emission Computed Tomography in Aerosol Medicine J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-30 John S. Fleming
Imaging of radiolabeled aerosols provides useful in vivo data on both the initial site of deposition and its subsequent transport by mucociliary clearance and epithelial permeability. Single Photon Emission Computed Tomography (SPECT) uses a gamma camera with multiple rotating heads to produce three-dimensional (3D) images of inhaled radioaerosol labeled with technetium-99m. This enables total lung
-
An Investigation into the Factors Associated with Incorrect Use of a Pressurized Metered-Dose Inhaler in Japanese Patients J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-27 Hiroshi Ohnishi, Masafumi Okazaki, Kazuki Anabuki, Shin Akita, Shigeo Kawase, Kimiko Sakai Tsuji, Mitsuhiko Miyamura, Akihito Yokoyama
Rationale: Inhalation of the correct dose of a short-acting beta 2 agonist (SABA) from a pressurized metered-dose inhaler (pMDI) is essential for the relief of symptoms in patients with asthma and/or chronic obstructive pulmonary disease. The aim of this study was to evaluate the prevalence and factors associated with the incorrect use of a pMDI.
-
Application of Machine Learning for Segmentation of the Pulmonary Acinus Imaged by Synchrotron X-Ray Tomography J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-19 Branko Arsic, Igor Saveljic, Frank S. Henry, Nenad Filipovic, Akira Tsuda
Background: To assess the effectiveness of inhalation therapy, it is important to evaluate the lungs' structure; thus, visualization of the entire lungs at the level of the alveoli is necessary. To achieve this goal, the applied visualization technique must satisfy the following two conditions simultaneously: (1) it has to obtain images of the entire lungs, since one part of the lungs is influenced
-
Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Alain Martin, Christopher Lupfer, Ronald Amen
Background: As an anti-inflammatory and antioxidant, sodium pyruvate significantly reduces inflammatory cytokines and oxygen radicals such as interleukin (IL) IL-6, IL-8, Monocyte Chemoattractant Protein-1, and hydrogen peroxide. Thus, sodium pyruvate holds promise as a treatment for many respiratory diseases, including allergic rhinitis (AR). Novel treatments for AR are needed as current medications
-
Comparison of Dose–Response Relationships for Two Isolates of SARS-CoV-2 in a Nonhuman Primate Model of Inhalational COVID-19 J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Paul A. Dabisch, Jaleal S. Sanjak, Jeremy A. Boydston, John Yeager, Artemas Herzog, Jennifer Biryukov, Katie Beck, Danh Do, Brittany G. Seman, Brian Green, Jordan K. Bohannon, Brian Holland, David Miller, Taylor Ammons, Denise Freeburger, Susan Miller, Tammy Jenkins, Sherry Rippeon, James Miller, David Clarke, Emmanuel Manan, Ashley Patty, Kim Rhodes, Tina Sweeney, Michael Winpigler, Louis A. Altamura
Background: As the COVID-19 pandemic has progressed, numerous variants of SARS-CoV-2 have arisen, with several displaying increased transmissibility.
-
Preclinical Studies of the Nebulized Delivery of Liposomal Amphotericin B J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Sagar Kothari, Steven G. Kefalos, Nicholas D. Hages, Timothy E. Corcoran, Shahid Husain
Background: Intravenous liposomal amphotericin B (L-AMB) has accompanying side effects that may be diminished when administering an inhaled form. Delivery systems for inhaled or aerosolized L-AMB vary, and there has not been a recent comparison of available systems to date.
-
Satisfaction with and Use of Inhalation Devices in Patients with Bronchial Asthma J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Luis Fernando Valladales-Restrepo, Juan Camilo Saavedra-Navia, Carlos Andrés Montezuma-Casanova, Valentina Montañez-Díaz, Jairo Andrés González-Ospina, Laura Manuela Caballero-Martínez, Andrés Gaviria-Mendoza, Manuel Enrique Machado-Duque, Jorge Enrique Machado-Alba
Background: Greater patient satisfaction with his or her inhalation device is associated with better adherence to pharmacological therapy and better clinical outcomes, such as improved quality of life, greater asthma control, and fewer exacerbations. The objective of this study was to determine the satisfaction level of a group of patients diagnosed with bronchial asthma concerning their devices for
-
Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Wade Cooper, Sutapa Ray, Sheena K. Aurora, Stephen B. Shrewsbury, Christopher Fuller, Greg Davies, John Hoekman
Oral tablets account for the majority of medications used to acutely treat migraine, but relief can be limited by their rates of dissolution and absorption. The nose is an attractive alternative route of drug delivery since it provides patient convenience of at-home use, gastrointestinal (GI) avoidance, and rapid absorption of drugs into systemic circulation because of its large surface area. However
-
Imaging Aerosol Deposition with Two-Dimensional Gamma Scintigraphy J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-12-13 Beth L. Laube
Several imaging modalities have been employed to quantify lung dose and the distribution of the dose of orally inhaled aerosols in vivo. Two-dimensional (2D, or planar) imaging using gamma scintigraphy is the most widely used of these modalities. Two-dimensional gamma scintigraphy studies are accomplished using a single- or dual-headed gamma camera. The formulation to be tested is admixed with the
-
Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 Ahmed H. Albariqi, Wei-Ren Ke, Dipesh Khanal, Stefanie Kalfas, Patricia Tang, Warwick J Britton, John Drago, Hak-Kim Chan
Background: Ivermectin has received worldwide attention as a potential COVID-19 treatment after showing antiviral activity against SARS-CoV-2 in vitro. However, the pharmacokinetic limitations associated with oral administration have been postulated as limiting factors to its bioavailability and efficacy. These limitations can be overcome by targeted delivery to the lungs. In this study, inhalable
-
Duplicate Prescription Rates of Long-Acting Bronchodilator Inhalers J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 Dekel Shlomi, Jacob Cohen, Adi Alon, Bernice Oberman, Irit Katz
Background: Long-acting bronchodilator inhalers are widely used with or without inhaled corticosteroids (ICs) by patients with lung diseases. In Israel alone, there are 21 inhalers containing long-acting β2 agonists (LABAs) and/or long-acting muscarinic antagonists (LAMAs). Some patients are treated incorrectly with several inhalers of the same pharmacologic group.
-
Inhalation Potential of Rifampicin-Loaded Novel Metal–Organic Frameworks for Improved Lung Delivery: Physicochemical Characterization, In Vitro Aerosolization and Antimycobacterial Studies J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 Sima Kujur, Arti Singh, Charan Singh
Background: The aim of the current study was to examine the potential of a rifampicin-loaded metal–organic framework (RIF@ZIF-8) for management of tuberculosis.
-
Suitability of Bronchoscopic Spraying for Fluid Deposition in Lower Airway Regions: Fluorescence Analysis on a Transparent In Vitro Airway Model J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 Stefanie Gürzing, Anja L. Thiebes, Christian G. Cornelissen, Stefan Jockenhoevel, Manuel A. Reddemann
Introduction: Bronchoscopic spraying has potential for the application of therapeutic drugs in distal regions of the lung by bypassing the upper airways. However, there is a lack of understanding about the underlying fluid transport phenomena that are responsible for the intrapulmonary propagation of applied liquid.
-
Relative Lung and Systemic Bioavailability Along with Oropharyngeal Deposition of Salbutamol Post-Inhalation: A Pharmacokinetic Evaluation of Novel Inhaler Technique Training Gadgets J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 Wesam G. Ammari, Mark Sanders
Background: Suboptimal use of pressurized metered dose inhaler (pMDI) remains a major barrier to inhaled therapy success. Verbal inhaler technique training (VT) fails to maintain patients' good pMDI use, thus training tools might help. Trainhaler® (THR device) and Flo-Tone® CR (FTCR device), two novel pMDI technique training tools, were evaluated and compared in terms of relative lung and systemic
-
Design of In Vivo Deposition and Clearance Experiments J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-11 William D. Bennett
Experiments designed to image in vivo deposition of radiolabel-drug mixtures are useful for estimating inhaled drug delivery and for assessing bioequivalence of delivery devices. Validation of the radiolabel-drug mixture is vital to ensure that subsequent imaging is reflective of drug deposition. Application of gamma attenuation corrections allows both total and regional lung deposition of drug to
-
Building on Strong Foundations: The Next Chapter in the Story of the Journal of Aerosol Medicine and Pulmonary Drug Delivery. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-10-01 Thomas O'Riordan
-
Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-08-04 Omar S. Usmani, Simonetta Baldi, Simon Warren, Ilaria Panni, Luca Girardello, François Rony, Glyn Taylor, Wilfried DeBacker, George Georges
Background: An extrafine formulation triple therapy combination of beclomethasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) has been developed for the maintenance treatment of asthma and chronic obstructive pulmonary disease. This study used gamma scintigraphy to evaluate the intrapulmonary and extrapulmonary in vivo deposition of BDP/FF/GB, and the intrapulmonary
-
Pilot Study to Investigate the Benefits of the InnoSpire Go Mesh Nebulizer Compared to Jet Nebulizers in the Treatment of Stable COPD J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-08-04 Cheryl Nickerson, Dirk von Hollen, Sara Garbin, Ketah Doty, Jeff Jasko, Chuck Cain
Background: Nebulizers are widely used for the delivery of aerosols to patients with chronic obstructive pulmonary disease (COPD). The InnoSpire Go mesh nebulizer has been designed to improve upon the ease of use and convenience of existing nebulizers for the treatment of COPD.
-
In Vitro Analysis of Nasal Interface Options for High-Efficiency Aerosol Administration to Preterm Infants J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-08-04 Connor Howe, Mohammad A.M. Momin, Karl Bass, Ghali Aladwani, Serena Bonasera, Michael Hindle, Philip Worth Longest
Background: An infant air-jet dry powder inhaler (DPI) platform has recently been developed that in combination with highly dispersible spray-dried powder formulations can achieve high-efficiency aerosolization with low actuation air volumes. The objective of this study was to investigate modifications to the nasal interface section of this platform to improve the aerosol delivery performance through
-
Microbiome Profiles of Nebulizers in Hospital Use J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-08-04 Clifford S. Swanson, Rajiv Dhand, Liu Cao, Jennifer Ferris, C. Scott Elder, Qiang He
Background: Nebulizers are used to provide treatment to respiratory patients. Concerns over nosocomial infection risks from contaminated nebulizers raise the critical need to identify all microbial populations in nebulizers used by patients. However, conventional culture-dependent techniques are inadequate with the ability to identify specific microbial populations only. Therefore, the aims of this
-
Radiolabeling Methods J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-08-04 Myrna B. Dolovich
In vivo measurements of the deposition of an inhaled radiolabeled pharmaceutic have provided useful information related to the inhaler efficiency for depositing drug in the lung. A number of labeling techniques have been developed and applied to pharmaceutical aerosols delivered by pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) and nebulizers; the choice of radiotracer depends
-
Adrenaline Inhalation Under Tracheal Intubation by High-Flow Nasal Cannula for Laryngeal Edema. J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-27 Kaname Uchida,Hidehito Ota,Mieko Maezawa,Kenichiro Hayashi,Hikoro Matsui
-
Empirical Deposition Correlations J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Andrew R. Martin, Warren H. Finlay
Traditionally, empirical correlations for predicting respiratory tract deposition of inhaled aerosols have been developed using limited available in vivo data. More recently, advances in medical image segmentation and additive manufacturing processes have allowed researchers to conduct extensive in vitro deposition experiments in realistic replicas of the upper and central branching airways. This work
-
Spray Drying and Particle Engineering in Dosage Form Design for Global Vaccines J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Mellissa Gomez, Reinhard Vehring
Vaccines are a very important tool in the effort to reduce the global burden of infectious diseases. Modern vaccines can be formulated in several ways to induce specific immunity, including through the use of live bacteria, subunit antigens, and even genetic material. However, vaccines typically need to be transported and stored under controlled refrigerated or frozen conditions to maintain potency
-
Optimal Inhalation Flow Pattern from Turbuhaler Predicted by Laser Photometry J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Tetsuri Kondo, Makoto Hibino, Toshimori Tanigaki, Sakurako Tajiri, Shigeto Horiuchi
Background: The emitted dose (ED) from most dry powder inhalers (DPIs) is almost independent of peak inspiratory flow (PIF) above a certain value, which is specific to the individual DPI. However, the ED of the Turbuhaler® (TBH) increases linearly with PIF increments. This study investigated the powder clearance and clinical utility of TBH performance features by using the photo-reflection method (PRM)
-
Effect of a Surfactant Additive on Drug Transport and Distribution Uniformity After Aerosol Delivery to Ex Vivo Lungs J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Nicholas D. Hages, John C. Sembrat, Lawrence Weber, Darragh J. Johnston, Amy Z. Stetten, Madeline Sauleda, Brian Mulhern, Robert D. Tilton, Stephen Garoff, Mauricio Rojas, Timothy E. Corcoran
Background: Inhaled drug delivery can be limited by heterogeneous dose distribution. An additive that would disperse drug over the internal surfaces of the lung after aerosol deposition could improve dosing uniformity and increase the treated area. Our previous studies demonstrated that surfactant additives can produce surface tension-driven (Marangoni) flows that effectively dispersed aerosol-delivered
-
In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Thomas Shepherd, Matthew Kennett, Andrew Cooper, Adrian Parkinson
Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The dosing performance of DPIs is dependent on the patient's inspiratory
-
Investigating the Accuracy of the Digihaler, a New Electronic Multidose Dry-Powder Inhaler, in Measuring Inhalation Parameters J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-06-10 Henry Chrystyn, Dinesh Saralaya, Anil Shenoy, Sophie Toor, Kari Kastango, Enric Calderon, Thomas Li, Guilherme Safioti
Background: The Digihaler® is a Food and Drug Administration-approved, digital multidose dry powder inhaler with an integrated electronic module that provides patients and health care professionals with feedback on inhalation parameters, including usage, adherence, and technique. This study compared inhalation parameters measured using the Digihaler with readings made simultaneously using an inhalation
-
Moving Forward from "Fine Particle Fraction: The Good and the Bad". J. Aerosol Med. Pulm. Drug Deliv. (IF 3.4) Pub Date : 2022-05-04 Jolyon P Mitchell,William Doub,J David Christopher,Christopher J Gruenloh,Rajni B Patel,Mark Copley,Steven Tignor,Stephen W Stein,Svetlana Lyapustina,Stephen P Newman